Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Prof Sarah De Val in collaboration with Dr Gillian Douglas from the Radcliffe Department of Medicine has received a grant from the John Fell Fund to support their work investigating the behaviour of different endothelial regulatory pathways during disorders of the cardiovascular system.

Sarah De Val.jpg

 

Endothelial cells (EC) form the inner lining of blood vessels and are essential for their function and homeostasis. Endothelial cells are highly heterogenous and can therefore behave very differently depending on the local environment. These differences are essential to form new blood vessels in areas of need, to adapt vessels to changes in the local environment, and to create and maintain different branches of the vasculature, which includes arteries and veins.

Identifying how these ECs behave in different situations is vitally important to understanding how the body attempts to repair itself after injury through the formation of new blood vessels, what can go wrong and how we can try to manipulate the behaviour of ECs to facilitate repair.

Associate Professor Sarah De Val’s lab aims to identify and describe the regulatory pathways responsible for controlling different aspects of EC behaviour. The team's recent research has characterised multiple independent regulatory pathways, and in order to do this, they have generated a number of novel enhancers: reporter transgenic mouse lines.

“With Prof Nicola Smart, we have already successfully used these transgenic models to investigate the regulatory pathways controlling different types of vessel growth in the heart, uncovering unexpected differences between the pathways involved in development, quiescence and response to injury” (Prof De Val). These findings could hold the key to understanding exactly how these pathways operate when the heart is damaged.

Prof De Val, in a close collaboration with Dr Gillian Douglas from the Radcliffe Department of Medicine, has now been awarded a £50,000 grant from the University of Oxford’s John Fell Fund to allow her to expand this investigation of EC regulatory pathways into different cardiovascular disease states.To do so, they plan to analyse and gather data from multiple models of common cardiovascular diseases in which incorrect EC behaviour is a key disease modulator. 

If they can establish the mechanisms behind EC dysfunction, their research could pave the way for understanding why these diseases develop and potentially inform the development of future therapeutic or even preventative strategies targeting the independent pathways.

Similar stories

The brain’s one-sided teaching signals

A new study by the Lak group reveals a novel facet of dopamine signalling during visual decision making.

The prime of Professor Dame Kay Davies

Professor Dame Kay Davies, Professor of Genetics, first woman appointed Dr Lee's Professor of Anatomy at Oxford, first woman to become Head of Department for DPAG, University-wide champion of equality, and award winning scientist known for her work on Duchenne muscular dystrophy, has 'retired' after a lifetime's research, but remains Professor Emeritus at DPAG.

Fellowship awarded to Huriye Atilgan to enhance our understanding of value-based decision-making

Congratulations are in order for Postdoctoral Research Scientist Dr Huriye Atilgan who has been awarded a prestigious Sir Henry Wellcome Postdoctoral Fellowship funded by the Wellcome Trust.

The future of stroke treatment

A team of international collaborators including DPAG's Dr Mootaz Salman has been researching a promising new therapeutic for the treatment of strokes and other brain injuries.

New review reveals proof of concept for an anti-obesity immunotherapy

The Domingos lab has published a new opinion piece in Science investigating the implications of a Memorial Sloan Kettering Cancer Center study that lays the foundations for a potential new anti-obesity treatment in the form of targeting adipose tissue-resident macrophages.